Want to see AHCO full AI Analyst Report?
Adjusted EBITDA Breakdown
Provides a detailed look at earnings before interest, taxes, depreciation, and amortization, offering insight into operational performance and cost management strategies.Adjusted EBITDA is heavily concentrated in Sleep and Respiratory, which remain the company’s resilient margin engines despite predictable Q1 troughs; by contrast Diabetes and Wellness at Home show genuine erosion—Wellness weakened from dispositions and Diabetes has a structural downtrend—creating the biggest risk to sustained margin improvement. Management’s large capitated win and refinancing improve the medium‑term outlook and should lift margins as membership ramps, but near‑term EBITDA and free‑cash‑flow are compressed by transition labor and elevated CapEx, with real benefit expected in the back half of the year.
Date | Sleep Health | Respiratory Health | Diabetes Health | Wellness at Home |
|---|---|---|---|---|
Jun 30, 2026 | $70.25M | $53.09M | $0.00 | $8.66M |
Mar 31, 2026 | $62.70M | $50.04M | $4.14M | $4.31M |
Dec 31, 2025 | $81.67M | $60.26M | $4.10M | $17.12M |
Sep 30, 2025 | $84.49M | $55.05M | $10.03M | $20.48M |
Jun 30, 2025 | $80.77M | $48.96M | $5.55M | $20.26M |
Mar 31, 2025 | $63.63M | $45.48M | $6.39M | $12.45M |
Dec 31, 2024 | $102.05M | $50.99M | $21.87M | $25.69M |
Sep 30, 2024 | $86.53M | $47.45M | $7.31M | $22.97M |
Jun 30, 2024 | $80.64M | $56.31M | $10.79M | $17.58M |
Mar 31, 2024 | $79.54M | $45.36M | $20.56M | $13.03M |